1Ryman D,Lamb BT.Genetic and environmental modifiers of Alzheimer's disease phenotypes in the mouse.Curr Alzheimer Res,2006,3:465-473.
2Mayeux R.Gene-environment interaction in late-onset Alzheimer disease:the role of apolipoprotein-epsilon 4.Alzheimer Dis Assoc Disord,1998,12 Suppl 3:10-15.
3Kamboh MI,Sanghera DK,Aston CE,et al.Gender-specific nonrandom association between the alpha 1-antichymotrypsin and apolipoprotein E polymorphisms in the general population and its implication for the risk of Alzheimer's disease.Genet Epidemiol,1997,14:169-180.
4Borroni B,Grassi M,Agosti C,et al.Genetic correlates of behavioral endophenotypes in Alzheimer disease:role of COMT,5-HTTLPR and ApoE polymorphisms.Neurobiol Aging,2006,27:1595-1603.
5Steiner H,Haass C.Intramembrane proteolysis by presenilins.Nat Rev Mol Cell Biol,2000,1:217-224.
6Cirrito JR,Kang JE,Lee J,et al.Endocytosis is required for gynaptic activity-dependent release of amyloid-beta in vivo.Neuron,2008,58:42-51.
7Koo EH,Squazzo SL.Evidence that production and release of amyloid beta-protein involves the endocytic pathway.J Biol Chem,1994,269:17386-17389.
8Hardy J,Selkoe DJ.The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics.Science,2002,297:353-356.
9Etcheberrigaray R,Tan M,Dewachter I,et al.Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice.Proc Natl Acad Sci USA,2004,101:11141-11146.
10Hwang EM,Kim SK,Sohn JH,et al.Furin is an endogenous regulator of alpha-secretase associated APP processing.Biochem Biophys Res Commun,2006,349:654-659.
